Strategic funding Leverage Enlaza’s strong and recent venture funding (notably 100M Series A in 2024 and 45M upfront in 2025 with potential milestone upside) to position as a partner for co-development or milestone-driven collaborations, especially in oncology and autoimmune platforms that align with covalent biologics.

Covalent biologics niche Target biotech and Pharma in need of highly specific, durable binding therapies by highlighting War-Lock covalent technology for first-in-class drug conjugates and T-cell engagers, opening conversations for license deals, strategic collaborations, or sponsored research.

Strategic alliance Capitalize on Vertex collaboration to explore parallel opportunities in autoimmune diseases and sickle cell conditioning; approach Vertex-like biologics/large pharma with joint development or expansion into additional targets and modalities using Enlaza’s War-Lock platform.

Pipeline potential Position Enlaza as a growth partner for early and mid-stage programs seeking novel covalent biologics; map potential partners to each pipeline candidate and prepare targeted outreach for co-development, licensing, or funding arrangements that accelerate clinical milestones.

Financial upside Highlight substantial upfront payments and milestone/royalty structures from investors and partners to present a compelling case for long-term collaboration budgets, supporting resourcing discussions, joint program financing, and scalable manufacturing planning.